All In Biotech

Drug Trial Radar · NCT04797104

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

478

Actual

Start

Apr 22, 2021

Primary completion

Jul 30, 2023

Study completion Dec 5, 2023

Sponsor

Lead sponsor
LIB Therapeutics LLCIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Mar 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.

Conditions

  • Heterozygous Familial Hypercholesterolemia

Interventions

  • lerodalcibepDrug

    300 mg Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24Time frame: Baseline and Week 24
  2. Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24Time frame: Baseline and Week 24

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Metabolic & Atherosclerosis Research Center (MARC)

    Cincinnati, Ohio

  • Rabin Medical Center, Beilinson Hospital,

    Petah Tikva, Israel

  • Department of Medicine, Hadassah University Hospital

    Jerusalem, Jerusalem, Israel

  • Lipid Clinic, Oslo University Hospital

    Oslo, Norway

  • Carbohydrate and Lipid Metabolism Research Unit

    Johannesburg, Gauteng, South Africa

  • Division of Lipidology, Department of Medicine University of Cape Town

    Cape Town, Western Province, South Africa

  • Ege University Medical School

    Izmir, Bornova, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.